SGLT2 inhibitor empagliflozin remodels pericardial fat–derived lipids-initiated ventricular ion‑channel function to reduce arrhythmogenic electrical remodeling in diabetic hearts

30 August 2026 (14:30 - 14:40)
Organised by: Logo
Congress Presentation Part of: Unexpected consequences of cardiometabolic disease Pathophysiology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology